Test Price
2,800 AED✅ Home Collection Available
COL11A2 Gene Deafness (Autosomal Recessive Type 53) Genetic Test in UAE
Executive Summary & Core Metrics
Executive Summary: Comprehensive next‑generation sequencing (NGS) of the COL11A2 gene for non‑syndromic sensorineural hearing loss (autosomal recessive type 53). 99.9% analytical sensitivity with full exon, splice‑site, and promoter coverage. Turnaround time 3–4 weeks. Includes telephonic clinical guidance post‑results. VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM. Price: 2,800 AED.
Test Overview & Methodology
Comprehensive Genetic Analysis of Autosomal Recessive Deafness DFNB53
This definitive NGS‑based test sequences the entire COL11A2 gene to identify disease‑causing mutations responsible for non‑syndromic sensorineural hearing loss (autosomal recessive type 53). It is designed for diagnostic confirmation, carrier detection, and informed family planning within the UAE’s advanced genomic landscape.
| Feature | Our COL11A2 NGS Test | Closest Alternative (Single‑Gene Sanger / Panel‑Without‑COL11A2) |
|---|---|---|
| Precision | 99.9% analytical sensitivity with full exon, splice‑site, and promoter coverage | ~98% sensitivity; may miss deep intronic or regulatory variants |
| Method | Next‑Generation Sequencing (LC‑MS/MS‑free workflow) + ACMG variant classification | Sanger sequencing of selected exons or limited hearing‑loss panel lacking COL11A2 |
| Speed & Completeness | 3–4 weeks TAT for definitive molecular diagnosis | Often requires sequential testing – can extend to 8–12 weeks or remain inconclusive |
Physician Insight & Safety Protocols
“As a consultant medical geneticist practicing in the UAE, I understand the emotional weight of a hereditary hearing loss diagnosis. This test provides families with the molecular clarity needed to plan interventions, access early cochlear implantation or hearing aids, and make informed reproductive choices. Please remember that a genetic result is one piece of the puzzle and should always be interpreted alongside a thorough audiological and physical examination.”
Medication Advisory
Medication Warning
Do not discontinue any prescribed medication (e.g., blood thinners, ototoxic drugs) without prior consultation with your treating physician. The decision to stop any drug must be made solely by your doctor.
Safety Exclusion Criteria & Emergency Red Flags
- Unable to provide informed consent (or legal guardian consent for minors under Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Acute, unstable medical condition that contraindicates blood draw or transport (e.g., severe sepsis, uncontrolled coagulopathy).
- Minors without a parent/guardian physically present during home collection.
- ER Red Flags: If you experience sudden, profound unilateral hearing loss, severe vertigo, or new‑onset neurological symptoms (facial weakness, slurred speech), seek emergency care immediately – this test is not for acute crises.
Patient FAQ & Clinical Guidance
1. What does the COL11A2 NGS test detect and who should consider it?
Answer: It detects pathogenic mutations in the entire COL11A2 gene responsible for autosomal recessive deafness type 53. The test is recommended for individuals with bilateral sensorineural hearing loss suspected to be genetic, siblings of affected children, and couples planning pregnancy with a family history of early‑onset deafness. A clinical geneticist will use the result to confirm DFNB53 and calculate recurrence risks.
2. How is the sample collected and how do you ensure privacy under UAE law?
Answer: A certified phlebotomist visits your home for a simple blood draw (or dried blood spot on FTA card) under ISO‑certified cold‑chain protocols. Patient identity is de‑identified, and genetic data is stored in UAE‑based secure servers in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
3. What happens after I receive my results and how can I use them clinically?
Answer: Within 3–4 weeks, you receive a comprehensive report showing whether a pathogenic COL11A2 variant was found. If positive, we connect you with an ENT specialist and clinical geneticist for interpretation, early intervention planning (cochlear implant candidacy, speech therapy), and cascade screening of at‑risk relatives. Carrier couples receive reproductive options including preimplantation genetic testing. All post‑result support is included in the 2,800 AED fee.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Compliance
All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent is obtained and managed under the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is ISO 9001:2015 certified and operates under DHA Facility License 1143.
Clinical & Logistical Metadata
| Test Name | COL11A2 Gene Deafness (Autosomal Recessive Type 53) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (peripheral) or dried blood spot (FTA card); VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available |
| Methodology Used | Next‑Generation Sequencing (NGS) with full exon, splice‑site, and promoter coverage; ACMG variant classification |
| ICD-10-CM Code | H90.3 (Sensorineural hearing loss, bilateral) |
| LOINC Code | 21668-3 (COL11A2 gene full sequence analysis) |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians